Table 4.
Efficacy of implementation (structured treatment pathway) vs. control (usual care) in changing GerdQ scores
| Average difference in GerdQ score change (Implementation – Control) | ||||
|---|---|---|---|---|
| n | Efficacy | (95% CI) | p-value | |
| Overall GerdQ* | 1734 | −0.61 | (−0.88 to −0.33) | < 0.001 |
| Overall GerdQ | 1734 | −0.61 | (−0.88 to −0.34) | < 0.001 |
| Heartburn | 1734 | −0.20 | (−0.30 to −0.11) | < 0.001 |
| Regurgitation | 1734 | −0.20 | (−0.29 to −0.11) | < 0.001 |
| Difficulty in sleep | 1734 | −0.13 | (−0.21 to −0.06) | 0.001 |
| Additional OTC medication | 1734 | −0.11 | (−0.19 to −0.03) | 0.008 |
Results in the table were estimated from mixed linear models with random intercepts for study centre (clinic). A negative estimate indicates that the implementation group was superior to the control group in reducing GerdQ scores.
*
Adjusted by country and baseline GerdQ score. All other analyses were further adjusted for age, sex, smoking and alcohol intake. CI, confidence interval; GerdQ, Gastro-oesophageal Reflux Disease Questionnaire; OTC, over the counter.